Market Cap | 18.46M | P/E | - | EPS this Y | 70.10% | Ern Qtrly Grth | - |
Income | -34.36M | Forward P/E | -1.42 | EPS next Y | 3.90% | 50D Avg Chg | -17.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -17.00% |
Dividend | N/A | Price/Book | 0.84 | EPS next 5Y | - | 52W High Chg | -62.00% |
Recommedations | 1.70 | Quick Ratio | 2.79 | Shares Outstanding | 10.74M | 52W Low Chg | 1.00% |
Insider Own | 14.87% | ROA | -176.03% | Shares Float | 4.55M | Beta | - |
Inst Own | 53.22% | ROE | - | Shares Shorted/Prior | 37.17K/20.82K | Price | 3.26 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 28,300 | Target Price | 16.38 |
Oper. Margin | - | Earnings Date | May 13 | Volume | 10,005 | Change | -0.91% |
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors, used for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Oppenheimer | Outperform | Apr 1, 24 |
HC Wainwright & Co. | Buy | Apr 1, 24 |
HC Wainwright & Co. | Buy | Mar 13, 24 |
JonesTrading | Buy | Feb 16, 24 |
HC Wainwright & Co. | Buy | Feb 13, 24 |
HC Wainwright & Co. | Buy | Jan 29, 24 |
Oppenheimer | Outperform | Nov 13, 23 |
EF Hutton | Buy | Jul 7, 23 |
EF Hutton | Buy | Jun 20, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
MIDDLETON FRED A | Director Director | Jan 23 | Buy | 3.7 | 679,384 | 2,513,721 | 30,292 | 01/25/24 |
Sanderling Venture Partners VI... | Director Director | Jan 23 | Buy | 3.7 | 679,384 | 2,513,721 | 30,292 | 01/25/24 |
WILSON ROBERT N | Director Director | Dec 11 | Buy | 3.30 | 506 | 1,670 | 182,161 | 12/13/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | Nov 07 | Buy | 3.34 | 2,000 | 6,680 | 18,840 | 11/08/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Nov 06 | Buy | 3.12 | 2,400 | 7,488 | 35,894 | 11/08/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Nov 03 | Buy | 2.8 | 14,949 | 41,857 | 33,494 | 11/07/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | Nov 06 | Buy | 3.1208 | 2,440 | 7,615 | 16,840 | 11/07/23 |
Hebbar Sudarshan | Chief Medical Office.. Chief Medical Officer | Nov 03 | Buy | 2.7389 | 36,000 | 98,600 | 46,000 | 11/07/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Aug 25 | Buy | 3.02 | 223 | 673 | 5,223 | 09/05/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Aug 21 | Buy | 3.26 | 2,464 | 8,033 | 4,264 | 08/23/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Jun 23 | Buy | 3.53 | 1,900 | 6,707 | 13,387 | 06/26/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | Jun 08 | Buy | 5.225 | 1,000 | 5,225 | 9,000 | 06/15/23 |
MIDDLETON FRED A | Director Director | Jun 09 | Buy | 5.20 | 714 | 3,713 | 11,714 | 06/09/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Jun 08 | Buy | 5.20 | 485 | 2,522 | 13,185 | 06/09/23 |
MIDDLETON FRED A | Director Director | Jun 06 | Buy | 5.04 | 1,000 | 5,040 | 11,000 | 06/08/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Jun 06 | Buy | 5.16 | 4,700 | 24,252 | 12,700 | 06/08/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | Jun 06 | Buy | 5.19 | 2,000 | 10,380 | 8,000 | 06/08/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | Jun 02 | Buy | 4.80 | 1,000 | 4,800 | 6,000 | 06/05/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | May 16 | Buy | 2.698 | 1,000 | 2,698 | 1,000 | 06/05/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | Jun 01 | Buy | 4.66 | 3,687 | 17,181 | 12,187 | 06/05/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | May 31 | Buy | 4.21 | 1,000 | 4,210 | 5,000 | 06/01/23 |
BJERKHOLT ERIC | Director Director | May 30 | Buy | 3.85 | 255 | 982 | 3,684 | 06/01/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | May 30 | Buy | 3.8616 | 2,000 | 7,723 | 8,000 | 06/01/23 |
BJERKHOLT ERIC | Director Director | May 23 | Buy | 3.268 | 500 | 1,634 | 3,429 | 05/24/23 |
Leheny A. Rachel | Chief Executive Offi.. Chief Executive Officer | May 23 | Buy | 3.3439 | 3,000 | 10,032 | 4,000 | 05/24/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | May 22 | Buy | 3.11 | 8,000 | 24,880 | 8,500 | 05/24/23 |
BJERKHOLT ERIC | Director Director | May 16 | Buy | 2.69 | 1,300 | 3,497 | 2,729 | 05/18/23 |
Hebbar Sudarshan | Chief Medical Office.. Chief Medical Officer | May 16 | Buy | 2.6999 | 10,000 | 26,999 | 10,000 | 05/18/23 |
Roberts Eric W | Chief Business Offic.. Chief Business Officer | May 16 | Buy | 2.7 | 8,300 | 22,410 | 1,800 | 05/18/23 |
BREUIL ROBERT S | Chief Financial Offi.. Chief Financial Officer | Mar 31 | Sell | 1.25 | 2,188 | 2,735 | 20,529 | 04/04/22 |